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Summary
In a multivariable analysis of cases with invasive H. influenzae, prematurity in infants, advanced 
age and certain chronic diseases in adults were associated with an increased risk of in-hospital 
death. Nontypeable disease was associated with higher mortality in the elderly.
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Since the introduction of the Hib conjugate vaccine in the United States, there has been a 
dramatic decrease of Hib among children less than 5 years of age (1, 2). With the decline of 
Hib, the relative importance of nontypeable H. influenzae as a cause of invasive disease has 
increased. Despite the absence of a capsule, nontypeable strains can still cause invasive 
disease. The bacterial factors in nontypeable strains that contribute to the pathogenesis of 
invasive disease are poorly defined, largely due to the genetic and phenotypic diversity of 
nontypeable strains (3, 4). Additionally, host factors that increase susceptibility to invasive 
nontypeable disease are not well understood.
Although many epidemiologic studies have reported mortality rates from invasive H. 
influenzae, these rates are often reported by age group, serotype, or clinical presentation. 
Only one study, to our knowledge, has performed a multivariable analysis to adjust for the 
relative contributions of such factors (5), and its findings have not been validated in other 
populations. Understanding risk factors for mortality is important to optimizing prevention 
strategies, which may someday include use of a non-Hib vaccine.
The goals of the current project are to describe the characteristics and clinical outcomes of 
pediatric and adult patients with invasive H. influenzae (HI) and, through multivariable 
analysis, identify risk factors for in-hospital mortality. The current report extends the 
analysis of surveillance data from the Active Bacterial Core surveillance (ABCs) program 
that was recently published (6).
Patients and Methods
Surveillance
Active, population- and laboratory based surveillance for HI was conducted from January 1, 
1999 through December 31, 2008 as part of Active Bacterial Core surveillance (ABCs). 
ABCs is supported by the U.S. Centers for Disease Control and Prevention (CDC) as part of 
its Emerging Infections Program (EIP) Network, as described elsewhere (7).
The surveillance area included 5 states and 5 metropolitan areas (6). The population under 
surveillance was 27,779,979 in 1999 and 35,559,550 in 2008 (representing 10.2% and 
11.7% of the US population in 1999 and 2008, respectively).
Definition of variables—A case of HI was defined as isolation of H. influenzae from a 
normally sterile site, which included blood, cerebrospinal fluid (CSF), synovial fluid or 
other sterile site aspirate; sputum and urine isolates were excluded. All cases were residents 
of a surveillance area. After case identification, the patient’s medical record at the treating 
facility was reviewed using a standard case report form. Community-acquired cases were 
defined as isolation in the community setting or within 48 hours of hospital admission, and 
healthcare-associated cases were defined as isolation more than 2 days after hospitalization. 
In-hospital mortality, or death with HI, was defined as death due to any cause prior to 
hospital discharge.
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Cases were classified by clinical syndromes in the following manner: a case was designated 
meningitis if a clinical diagnosis of meningitis had been entered into the patient’s medical 
record or if H. influenzae was isolated from the CSF; pneumonia was defined at having a 
diagnosis of pneumonia entered in the medical record and H. influenzae isolated from blood 
or pleural fluid during the hospital admission. When H. influenzae was isolated from blood 
and no other localized clinical syndrome was described, the case was classified as 
bacteremia without an identifiable focus.
The following underlying conditions were recorded from abstraction of the medical record: 
alcohol use, asthma, atherosclerotic heart disease (ASCVD), CSF leak, cirrhosis, cerebral 
vascular accident (CVA), chronic obstructive pulmonary disease (COPD), diabetes mellitus, 
dialysis, heart failure, HIV infection, intravenous drug use (IVDU), nephrotic syndrome, 
smoking, and systemic lupus erythematosus. In addition, a designation of 
immunocompromised state was utilized if the case patient had asplenia, immunoglobulin 
deficiency, sickle cell disease, current immunosuppressive therapy or a history of organ 
transplantation. Hematologic malignancies included lymphoma, leukemia, and multiple 
myeloma. Non-hematologic malignancies included all other malignancies, excluding basal 
cell and squamous cell cancer of the skin. Prematurity was defined as birth prior to 37 weeks 
gestational age. Prematurity was not included on the standard case report form but was 
determined based on written comments or gestational age less than 37 weeks at birth, if 
available at chart abstraction.
Chart abstraction for underlying conditions was performed from 1999–2008 at surveillance 
sites in CA, CT, MN, NY, OR and TN. GA and CO began recording underlying conditions 
in 2000, MD in 2001, and NM in 2004. NY did not collect information on HIV. 
Documentation of smoking status was initiated in 2000, and CVA was added in 2001.
Laboratory Methods
In this analysis, H. influenzae isolates were classified based on their serotype; serotype b 
(Hib), nontypeable (non-encapsulated), and non-b (serotypes a, c, d, e, and f). The term 
“encapsulated” includes Hib and non-b serotypes.
Serotyping of H. influenzae was performed at state public health laboratories. Isolates were 
sent to the CDC, where serotype was confirmed by slide agglutination. Serotyping results 
were discordant in 6% (256/4191) of the serotyped isolates. In most discordant cases, an 
isolate was found to be typeable at one laboratory and nontypeable at the other (n=246). In 
addition, a total of 702 isolates from the Georgia surveillance site were confirmed by 
capsule gene PCR. For this analysis, the CDC slide agglutination serotype result or the 
capsule-gene PCR serotype for Georgia isolates was used as the final serotype. If an isolate 
was non-viable or contaminated on arrival to the CDC, the result from the state laboratory 
was used.
A molecular analysis of 297 strains classified as nontypeable confirmed that 294 were 
indeed nontypeable; only 3 were H. haemolyticus (S. Satola, personal communication).
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When medians were calculated, a corresponding interquartile range (IQR) was determined. 
Categorical variables were compared using the χ2 test or, if the sample size was small, the 
Fisher’s exact test. Continuous variables were compared with the t test. A p-value < 0.05 
was considered significant.
A logistic regression model was developed to identify predictors of in-hospital mortality. 
Separate models were developed for children (<1 and 1–17 years) and adults (≥ 18 years). 
Cases with incomplete data were excluded from the model. For the adult model, the main 
predictor variables were serotype and clinical syndrome. Other factors associated with 
mortality (p-value <0.10) on univariate analysis were also included in the model. 
Collinearity was assessed with a validated macro (8). All possible two-way interactions were 
evaluated for the 2 main variables of interest: serotype and clinical syndromes. The 
likelihood ratio test was used to compare a non-interaction to an interaction model for each 
series of potential interacting terms. Variables were removed from the model using 
backward selection, requiring a p-value of less than 0.05 to remain, until the most 
parsimonious model was achieved. Model aptitude was evaluated with the c-statistic. All 
statistical analysis was done with SAS version 9.2 (SAS Institute, Cary, North Carolina). 
This study was approved by Emory University’s Institutional Review Board.
Results
A total of 4,839 cases of HI were identified between 1999 and 2008; 93.6% were 
community-acquired and 6.4% were healthcare-associated. Of the 3,928 community-
acquired strains available for serotyping, 68.5% were nontypeable, 27.8% were non-b, and 
only 3.7% were Hib. Of 263 healthcare-associated infections with known serotype, 85.6% 
were nontypeable, 12.5% non-b, and 1.9% type b. Among children, healthcare-associated 
cases occurred a median of 7 days after admission (IQR 3–10), and in adults, healthcare-
associated cases occurred a median of 5 days after admission (IQR 4–9).
Children accounted for 828 (17.1%) and adults 4,011 (82.9%) HI cases during the 
surveillance period. The median age among children was 1.1 years (IQR 83 days-4.4 years), 
and the median age in adults was 67.7 years (IQR 51.5–80.7).
Demographic characteristics and incidence rates for this surveillance period have been 
described elsewhere.(6) Tables 1a and 1b show the prevalence of serotypes, clinical 
syndromes, underlying conditions, and outcomes by age group.
Among the 828 pediatric cases, 174 (21.0%) occurred within 28 days after birth. 161 
(92.5%) of these neonatal cases were early-onset (<7 days after birth) and 13 (7.5%) were 
late-onset (≥7 days after birth). Nearly half of all cases occurring in infants less than 3 
months of age were in premature infants. Overall, gestational age was available for 147 
infants with HI: 44 (29.9%) were < 28 weeks, 41 (27.9%) were 28–33 weeks, 22 (15.0%) 
were 34–36 weeks, and 40 (27.2%) were ≥ 37 weeks. Birth weights for these 147 infants 
were as follows: 36 (24.5%) were < 1000 grams, 31 (21.1%) were 1000–1499 grams, 25 
(17.0%) were 1500–2499 grams, and 55 (37.4%) were ≥ 2500 grams. The highest mortality 
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rates were seen in the infants < 28 weeks gestational age (36.4%) or < 1000 grams at birth 
(36.1%). Of 35 infants who died, 30 (85.7%) had nontypeable HI disease, 2 (5.7%) had non-
b disease, and 3 (8.6%) were infected with strains of unknown serotype.
Underlying conditions were present in 247 of 805 (30.7%) children; 5.2% of children had 
more than 1 underlying condition. Among children, the most common underlying conditions 
were prematurity (14.3%), asthma (7.0%), and an immunocompromised state (6.7%).
Underlying conditions were present in 2869 of 3838 (74.8%) adults; 23.0% of adults had 2 
underlying conditions, and 24.5% had 3 or more. In adults, the most common underlying 
conditions were COPD (21.9%), diabetes (19.4%), and ASCVD (18.8%).
As shown in Tables 1a and 1b, hospitalization rates were highest in the ≥ 65 age group 
(94.9%) and in infants < 3 months (94.1%). Infants < 3 months had the longest hospital 
stays with a median duration of 11 days (IQR 7–30). In-hospital mortality was highest in 
cases ≥ 65 years (21.9%), followed by those < 3 months (16.2%) and 40–64 years (12.4%). 
Mortality rates varied by serotype: type a 7.8% (7/90), type b 10.1% (15/149), type c 27.3% 
(8/11), type d 42.9% (6/14), type e 12.3% (29/236), type f 9.8% (75/762), nontypeable 
17.3% (501/2895), and unknown serotype 16.6% (106/637). Overall in-hospital mortality 
was 11.0% for infections due to encapsulated strains.
Comparison between nontypeable and encapsulated HI disease
Adults with nontypeable HI were significantly older than adults with encapsulated HI (66.6 
vs. 62.8 years, p<0.01). Both adults and children with nontypeable HI had significantly 
longer lengths of hospital stay than encapsulated cases (children: 17.7 vs. 9.1 days, p<0.01; 
adults: 10.4 days vs. 8.6 days, p<0.01). Compared to encapsulated HI, nontypeable disease 
was more likely to cause bacteremia without an identifiable focus, a difference most notable 
among children (61.2% vs. 28.3%, p<0.01) but also seen in adults (31.1% vs. 26.0%, 
p<0.01). Nontypeable strains were less likely than encapsulated strains to cause pediatric 
meningitis (11.0% vs. 33.5%, p<0.01). Nontypeable HI was associated with higher mortality 
rates than encapsulated HI in infants <1 year of age and in adults (infants <1 yr 14.6% vs. 
5.7%%, p=0.01; adults 18.8% vs. 12.2%, p<0.01).
Children with nontypeable HI were more likely to be premature infants than those with 
encapsulated disease (21.6% vs. 1.9%, p<0.01). Several underlying conditions were 
significantly more common in adults with nontypeable HI than those with encapsulated HI, 
including ASCVD (21.0% vs. 16.1%, p<0.01), CSF leak (0.5% vs 0, p=0.04), dialysis (8.2% 
vs. 4.5%, p<0.01), heart failure (19.8% vs. 9.7%, p<0.01), hematologic malignancy (7.2% 
vs. 4.8%, p<0.01), and non-hematologic malignancies (11.3% vs. 7.3%, p<0. 01). Compared 
to cases with nontypeable HI, adult cases of encapsulated HI were more likely to use alcohol 
(8.3% vs. 5.9%, p=0.01), smoke (21.8% vs. 4.7%, p<0.01), have asthma (10.0% vs. 7.1%, 
p<0.01), HIV (7.1% vs. 3.3%, p<0.01), or IVDU (3.3% vs. 1.3%, p<0.01).
Predictors of in-hospital death
Characteristics associated with in-hospital mortality on univariate analysis are shown in 
Table 2. There were 648 cases of unknown serotype, all of which were excluded from this 
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analysis. No significant differences were noted in length of hospitalization or rates of death 
between cases of known and unknown serotype. Cases of unknown serotype, however, were 
significantly older (56.8 vs. 54.2 years, p=0.04).
Two pediatric models were constructed using variables that had a p-value <0.10 on 
univariate analysis. The first model for children < 1 year of age had 360 cases and included 
the following variables: age < 3 months, race, prematurity (<28 weeks, and 28–36 weeks), 
and serotype. After backward selection, only prematurity was associated with in-hospital 
death: <28 weeks (OR 7.1, 95% CI 3.2–15.6), 28–36 weeks (OR 2.1, 95% CI 0.9–4.8). The 
model for children aged 1–17 years had 372 cases and included the following variables: 
bacteremia without identifiable focus, dialysis, hematologic malignancy and healthcare-
associated HI. After backward selection, healthcare-associated HI (OR 5.66, 95% CI 1.84–
17.39) and dialysis (OR 18.11, 95% CI 2.77–118.65) were associated with in-hospital death.
In adults, 18 variables with a p-value <0.10 on univariate analysis were included in the 
logistic regression model (Table 2). No collinearity was present. Interaction was detected 
between age and serotype (nontypeable vs. encapsulated) using the likelihood ratio test 
(p=0.02). Among cases with nontypeable HI, patients ≥ 40 years had greater in-hospital 
mortality than cases 18–39 years (40–64 years: OR 1.97, 95% CI 1.05–3.67; ≥ 65 years: OR 
4.01, 95% CI 2.20–7.32). However, increasing age did not significantly increase the risk of 
death in cases of encapsulated disease. The presence of HI due to nontypeable strains was 
significantly associated with increased in-hospital death in those 65 years of age and older 
(OR 1.81, 95% CI 1.31–2.52). Other factors associated with in-hospital death in 
multivariable analysis, as shown in Table 3, were healthcare-associated HI (OR 2.42, 95% 
CI 1.66–3.53), bacteremia without identifiable focus (OR 2.74, 95% CI 1.70–4.42), 
bacteremic pneumonia (OR 2.11, 95% CI 1.32–3.36) and the presence of the following 
underlying conditions: cirrhosis (OR 3.74, 95% CI 2.24–6.25), CVA (OR 2.10, 95% CI 
1.45–3.06) dialysis (OR 1.74, 95% CI 1.24–2.45), heart failure (OR 1.53, 95% CI 1.19–
1.97), and non-hematologic malignancies (OR 1.81, 95% CI 1.34–2.46). Patients with 
asthma were less likely to die with HI (OR 0.60, 95% CI 0.38–0.95). The area under the 
Receiver Operating Characteristic (ROC) curve for the final model indicated good 
discrimination (c=0.712).
Discussion
With the dramatic decline of Hib disease, the relative importance of nontypeable HI has 
increased. The overall incidence of invasive nontypeable HI remains low in countries like 
the United States (1 per 100,000 persons), but rates of nontypeable disease are higher at the 
extremes of age (6, 9, 10). In addition, nontypeable strains now account for over half of all 
cases of invasive H. influenzae disease in the US and other parts of the world (11–14). 
Despite their diminished virulence, nontypeable strains can result in serious disease. In the 
current study, nontypeable HI was associated with longer hospital stays and higher mortality 
rates than encapsulated disease in both children and adults. The health status of the patient is 
likely to be a factor in susceptibility to nontypeable HI disease and to less favorable clinical 
outcomes.
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The current study reiterates the importance of nontypeable HI as a neonatal pathogen (15). 
In infants < 3 months of age with invasive HI, 82% of disease was due to nontypeable 
strains and 86% of all in-hospital deaths were associated with nontypeable strains. Many of 
the infections in neonates occurred within one week of birth, suggesting acquisition during 
labor and delivery or in utero.
Prematurity was common among infants with HI, as has been seen in other studies (16, 17). 
More than a quarter of all children with HI had underlying conditions. Others have reported 
a higher prevalence (41–70%) of underlying conditions in children with HI (4, 18), but one 
of these studies reflected the experience of a single tertiary care center (4) and the other 
represented a smaller population than the current project (18).
Prematurity was the lone factor predictive of death with HI in children < 1 year of age, and 
the risk was higher among babies <28 weeks. Since documentation of prematurity was not 
uniformly recorded on the case report form during the 1999–2008 study period, it is possible 
that the prevalence was under-reported and thus, the association between prematurity and 
death may be underestimated.
The prevalence of underlying conditions among adults in this cohort (74.8%) was similar to 
other reports (19–21). With the decline of encapsulated disease, the traditional risk factors 
for HI (e.g. defects in humoral immunity, asplenia) may be changing. In the current study, 
certain co-morbidities in adults were more likely to be associated with nontypeable rather 
than encapsulated HI, including ASCVD, heart failure, dialysis, and malignancy. None of 
these conditions confers a specific immune defect, suggesting that predisposition to 
nontypeable disease is multifactorial. The high prevalence of cardiovascular disease among 
cases of nontypeable HI has been previously described (10).
In the current project, the relationship between nontypeable HI and in-hospital death among 
those ≥ 65 years of age persisted even after adjusting for other predictors of death. Although 
prior studies have identified a high case-fatality rate for nontypeable strains, particularly in 
the elderly, these studies have not used a multivariable analysis to define the relative 
contribution of nontypeable disease (6, 9, 10). The current analysis also determined that 
increasing age, a common risk factor for worse outcomes, was only associated with higher 
mortality rates in nontypeable infections but not in encapsulated infections. Since 
nontypeable strains have been considered less likely to cause invasive disease than 
encapsulated strains (22), this association may reflect the relative importance of the host’s 
susceptibility rather than virulence of the nontypeable pathogen. Adults who developed 
nontypeable infections may have been more debilitated with significant underlying illnesses 
than those who developed encapsulated infections. The current project, however, did not 
document the functional status of case patients or severity of underlying diseases.
Several underlying conditions were associated with in-hospital death in adults, including 
cirrhosis, CVA, dialysis, heart failure, and non-hematologic malignancies. Dialysis was also 
associated with in-hospital death in children 1–17 years of age. A better understanding of 
those at risk for poor outcomes with HI may become particularly relevant if a nontypeable or 
universal HI vaccine is developed. Older adults may be candidates for a nontypeable 
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vaccine, although vaccine responsiveness would be a concern (23). A vaccine that used H. 
influenzae-derived protein D as a carrier protein for pneumococcal polysaccharides showed 
a decrease in otitis media due to both S. pneumoniae and nontypeable H. influenzae among 
children (24), but it has yet to be shown whether a similar approach would work for other 
nontypeable HI infections.
The current study has several strengths. Using active, population-based surveillance, the 
characteristics of HI in a large cohort were closely monitored over 10 years. Isolates were 
collected for serotype verification and clinical and demographic information was recorded 
from the medical records. Few studies have achieved the power to assess the association of 
comorbidities, clinical and isolate characteristics with outcomes of HI, as has been done in 
the current project.
The study has several limitations. First, the multivariable analysis reflects only in-hospital 
mortality, which is not a complete measure of overall clinical outcome and does not 
determine whether in-hospital deaths were attributable to HI. In addition, although data were 
carefully collected on the presence of underlying conditions, the severity of these conditions 
was not quantified. Controlling for the overall debilitation of the patient may provide a 
better understanding of the association between nontypeable HI and death. Finally, the 
sample size for the pediatric models was relatively small, which resulted in less precise 
estimations.
In conclusion, invasive H.influenzae is now primarily an infection associated with 
nontypeable strains in adults with chronic diseases. On multivariable analysis, in-hospital 
death was associated with prematurity in infants, dialysis and healthcare-associated onset in 
older children, and a number of chronic diseases in adults. Nontypeable HI was associated 
with increased mortality in the elderly. Further investigation is needed to better understand 
the host factors that predispose to serious infection and poor outcomes associated with 
nontypeable HI and to help identify those who would benefit from future HI vaccines.
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Table 3
Predictors of in-hospital mortality in 2877 adult cases of invasive H. influenzae determined by logistic 
regression
Variable Odds ratio (95% CI)
Age: 40–64 vs. 18–39 yrs
nontypeable 1.97 (1.05–3.67)
encapsulated 1.29 (0.51–3.23)




18–39 yrs 0.82 (0.48–1.40)
40–64 yrs 1.02 (0.65–1.60)
≥ 65 yrs 1.81 (1.31–2.52)
Healthcare-associated HI 2.42 (1.66–3.53)
Bacteremia without identifiable focus 2.74 (1.70–4.42)





Heart failure 1.53 (1.19–1.97)
Non-hematologic malignancy 1.81 (1.34–2.46)
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